Info

Glenmark Pharmaceuticals Limited [Glenmark] is an India-based growing pharmaceutical company headquartered at Mumbai [formerly, Bombay]. Incorporated in 1977, the company is focused on the manufacture and marketing of formulation products and active pharmaceutical ingredients in India as well as globally and enjoys a diversified and growing presence in regulated and developing international markets. Over the past five years, the company has also catalysed its growth through investment in dedicated research and development including cutting-edge New Chemical Entity research. Global Footprint Glenmark has built a visible and growing branded generic formulation presence across all its markets in Asia, Africa and CIS countries. A number of its products have emerged as brand leaders in India and these markets. Glenmark established its operations in Brazil in FY 2004 and acquired a company early FY 2005. The company also incorporated subsidiaries in the regulated markets of USA in FY 2003 and EU in FY 2005 and is making significant investments to build a strong API and generic formulations business in these markets. In all, the company operates in over 65 markets for formulations and also supplies APIs to over 45 markets globally. Manufacturing Capabilities Over the years, Glenmark has strengthened its integration across the pharmaceutical valuechain through operations across its various manufacturing plants: Formulations: Sao Paolo [Brazil], Nasik, Goa and Baddi [project] APIs: Ankleshwar, Kurkumbh and Solapur The Ankleshwar plant acquired from GlaxoSmithKline has now received USFDA acceptance. The API manufacturing facility recently acquired at Solapur focuses on intermediate and semi-regulated market APIs. The company has also recently commissioned a state-of-the-art formulation plant at Goa, built in stringent compliance with USFDA , EU and other regulated market standards. An ANVISA approved formulations facility in Brazil was also recently acquired. Research and Development Research lies at the heart of Glenmark's existence as enshrined in its vision. Its state-of-art R&D centre in Navi Mumbai [New Bombay] employs over 350 scientists who possess a vast experience across several disciplines and technology platforms. The research activities encompass process engineering for APIs, new chemical entity research [NCE] and novel drug delivery systems [NDDS]. The company also operates a second research facility at Sinnar that focuses on developing formulations for India and markets across Asia, Africa, Latin America and CIS/Russia. Glenmark is amongst the few Indian Pharmaceutical Companies to have taken initiative to invest proactively in original drug discovery research. In a span of three years Glenmark's R&D team has also successfully developed one Novel Drug Lead for Asthma and COPD. This PDE4 inhibitor has succesfully completed Phase I clinical trials in the UK and has been licensed out to Forest Laboratories, USA for North America and Teijin Pharma Limited for the Japan territory. The company is further researching PDE4 inhibitors for CNS indications, cognitive disorders and inflammatory conditions such as atopic dermatitis, ulcerative colitis and rheumatoid arthritis. Other research areas includes Diabetes segment in which the company has a DPP IV target, GRC 8200, in late pre-clinical trials.